FDA approves Basaglar, the first “follow-on” insulin glargine product for TI & TII

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Read more

Posted in Type I Type II Drugs